(Q38943401)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25362855%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

title

A kinase inhibitor screen identifies Mcl-1 and Aurora kinase A as novel treatment targets in antiestrogen-resistant breast cancer cells (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25362855%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

0 references

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25362855%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

author name string

A M Pedersen

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25362855%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

M B H Thomsen

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25362855%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

T Kirkegaard

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25362855%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

B B Rasmussen

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25362855%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

A K Duun-Henriksen

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25362855%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

A V Lænkholm

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25362855%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

M Bak

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25362855%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

A E Lykkesfeldt

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25362855%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

C W Yde

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25362855%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

language of work or name

English

0 references

publication date

3 November 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25362855%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25362855%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

volume

34

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25362855%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

issue

32

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25362855%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

page(s)

4199-4210

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25362855%20AND%20SRC:MED&resulttype=core&format=json

describes a project that uses

22 February 2020

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.351

Breast cancer: current and future endocrine therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.351

Biological determinants of endocrine resistance in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.351

Therapeutic implications of estrogen receptor signaling in HER2-positive breast cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.351

Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.351

Changes in breast cancer biomarkers in the IGF1R/PI3K pathway in recurrent breast cancer after tamoxifen treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.351

Determination of HER2 phosphorylation at tyrosine 1221/1222 improves prediction of poor survival for breast cancer patients with hormone receptor-positive tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.351

Activation of ErbB3, EGFR and Erk is essential for growth of human breast cancer cell lines with acquired resistance to fulvestrant

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.351

Breast cancer cells can switch between estrogen receptor alpha and ErbB signaling and combined treatment against both signaling pathways postpones development of resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.351

Estrogen receptor α is the major driving factor for growth in tamoxifen-resistant breast cancer and supported by HER/ERK signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.351

NFκB signaling is important for growth of antiestrogen resistant breast cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.351

FOXA1 is a key determinant of estrogen receptor function and endocrine response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.351

Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.351

Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.351

Protein Kinase C alpha is a marker for antiestrogen resistance and is involved in the growth of tamoxifen resistant human breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.351

Antiestrogen-resistant human breast cancer cells require activated protein kinase B/Akt for growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.351

Lapatinib restores hormone sensitivity with differential effects on estrogen receptor signaling in cell models of human epidermal growth factor receptor 2-negative breast cancer with acquired endocrine resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.351

Activation of a novel Bcr/Abl destruction pathway by WP1130 induces apoptosis of chronic myelogenous leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.351

Bcr-Abl ubiquitination and Usp9x inhibition block kinase signaling and promote CML cell apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.351

Sequential versus combined treatment of human breast cancer cells with antiestrogens and the vitamin D analogue EB1089 and evaluation of predictive markers for vitamin D treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.351

Anti-oestrogen resistant human breast cancer cell lines are more sensitive towards treatment with the vitamin D analogue EB1089 than parent MCF-7 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.351

Human breast cancer cell lines resistant to pure anti-estrogens are sensitive to tamoxifen treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.351

Breast cancer cells with acquired antiestrogen resistance are sensitized to cisplatin-induced cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.351

A competitive stapled peptide screen identifies a selective small molecule that overcomes MCL-1-dependent leukemia cell survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.351

The in vitro and in vivo effects of JNJ-7706621: a dual inhibitor of cyclin-dependent kinases and aurora kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.351

Validating survivin as a cancer therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.351

Mitosis-specific phosphorylation of histone H3 initiates primarily within pericentromeric heterochromatin during G2 and spreads in an ordered fashion coincident with mitotic chromosome condensation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.351

Aurora kinase inhibitors--rising stars in cancer therapeutics?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.351

The role of the epidermal growth factor receptor in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.351

Oestrogen receptor-mediated modulation of the EGFR/MAPK pathway in tamoxifen-resistant MCF-7 cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.351

Deubiquitinase inhibition by small-molecule WP1130 triggers aggresome formation and tumor cell apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.351

Mcl-1; the molecular regulation of protein function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.351

The antiapoptotic gene mcl-1 is up-regulated by the phosphatidylinositol 3-kinase/Akt signaling pathway through a transcription factor complex containing CREB

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.351

Epidermal growth factor regulates Mcl-1 expression through the MAPK-Elk-1 signalling pathway contributing to cell survival in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.351

Herceptin sensitizes ErbB2-overexpressing cells to apoptosis by reducing antiapoptotic Mcl-1 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.351

Myeloid cell leukemia-1 inversely correlates with glycogen synthase kinase-3beta activity and associates with poor prognosis in human breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.351

Bcl-2 inhibitors: small molecules with a big impact on cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.351

Inhibition of aurora B kinase blocks chromosome segregation, overrides the spindle checkpoint, and perturbs microtubule dynamics in mitosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.351

Aurora-A and an interacting activator, the LIM protein Ajuba, are required for mitotic commitment in human cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.351

Mitotic phosphorylation of histone H3: spatio-temporal regulation by mammalian Aurora kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.351

ERBB2 influences the subcellular localization of the estrogen receptor in tamoxifen-resistant MCF-7 cells leading to the activation of AKT and RPS6KA2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.351

Mcl-1 regulation and its role in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.351

Aurora kinase A outperforms Ki67 as a prognostic marker in ER-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.351

Aurora-A is a determinant of tamoxifen sensitivity through phosphorylation of ERα in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.351

Expression of aurora kinase A is associated with metastasis-free survival in node-negative breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.351

Growth inhibition and growth stimulation by estradiol of estrogen receptor transfected human breast epithelial cell lines involve different pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.351

Mcl-1 is critical for survival in a subgroup of non-small-cell lung cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.351

The regulatory beta-subunit of protein kinase CK2 regulates cell-cycle progression at the onset of mitosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.351

The clinical database and the treatment guidelines of the Danish Breast Cancer Cooperative Group (DBCG); its 30-years experience and future promise

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.351

Semi-quantitative scoring of potentially predictive markers for endocrine treatment of breast cancer: a comparison between whole sections and tissue microarrays

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.351

An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.351

ICI 182,780 (Faslodex): development of a novel, "pure" antiestrogen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.351

Differential oestrogen receptor binding is associated with clinical outcome in breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.351

The aurora kinases in cell cycle and leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.351

Altered expression of estrogen-regulated genes in a tamoxifen-resistant and ICI 164,384 and ICI 182,780 sensitive human breast cancer cell line, MCF-7/TAMR-1.

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25362855

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Effect of estrogen and antiestrogen on the human breast cancer cell line MCF-7 adapted to growth at low serum concentration

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25362855

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Estrogen promotes chemotherapeutic drug resistance by a mechanism involving Bcl-2 proto-oncogene expression in human breast cancer cells

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25362855

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/ONC.2014.351

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25362855%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

22 February 2020

1030685832

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25362855%20AND%20SRC:MED&resulttype=core&format=json